Fate Therapeutics Inc. (NASDAQ: FATE) is -46.18% lower on its value in year-to-date trading and has touched a low of $4.02 and a high of $43.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FATE stock was last observed hovering at around $5.55 in the last trading session, with the day’s loss setting it -0.12%.
Currently trading at $5.43, the stock is -30.07% and -61.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.64 million and changing -2.16% at the moment leaves the stock -76.95% off its SMA200. FATE registered -85.38% loss for a year compared to 6-month loss of -82.34%.
The stock witnessed a -55.67% gain in the last 1 month and extending the period to 3 months gives it a -71.85%, and is -5.07% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.66% over the week and 8.71% over the month.
Fate Therapeutics Inc. (FATE) has around 449 employees, a market worth around $545.01M and $69.00M in sales. Distance from 52-week low is 35.07% and -87.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.00%).
Fate Therapeutics Inc. (FATE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Fate Therapeutics Inc. (FATE) is a “Hold”. 24 analysts offering their recommendations for the stock have an average rating of 2.60, where 15 rate it as a Hold and 1 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Fate Therapeutics Inc. is expected to release its quarterly report on 05/03/2023.The EPS is expected to shrink by -6.40% this year.
Fate Therapeutics Inc. (FATE) Top Institutional Holders
The shares outstanding are 97.02M, and float is at 95.67M with Short Float at 23.34%.
Fate Therapeutics Inc. (FATE) Insider Activity
A total of 8 insider transactions have happened at Fate Therapeutics Inc. (FATE) in the last six months, with sales accounting for 8 and purchases happening 0 times. The most recent transaction is an insider purchase by MENDLEIN JOHN,the company’sDirector. SEC filings show that MENDLEIN JOHN bought 36,631 shares of the company’s common stock on Jan 13 at a price of $5.43 per share for a total of $0.2 million. Following the purchase, the insider now owns 0.28 million shares.
Fate Therapeutics Inc. disclosed in a document filed with the SEC on Jan 11 that MENDLEIN JOHN (Director) bought a total of 88,048 shares of the company’s common stock. The trade occurred on Jan 11 and was made at $5.67 per share for $0.5 million. Following the transaction, the insider now directly holds 0.25 million shares of the FATE stock.
Still, SEC filings show that on Jan 10, Valamehr Bahram (Chief R&D Officer) disposed off 10,917 shares at an average price of $5.24 for $57205.0. The insider now directly holds 168,917 shares of Fate Therapeutics Inc. (FATE).
Fate Therapeutics Inc. (FATE): Who are the competitors?
The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 34.10% up over the past 12 months and Neurocrine Biosciences Inc. (NBIX) that is 44.69% higher over the same period. Becton Dickinson and Company (BDX) is -4.75% down on the 1-year trading charts.